What is T-knife?
Founded in 2018 as a spin-off from the Max Delbruck Center for Molecular Medicine with support from Charité University Hospital, T-knife is dedicated to bringing sophisticated T cell receptor-based therapeutics to market. The company operates within the competitive landscape of advanced cell therapy, aiming to address unmet medical needs through its innovative platform.
How much funding has T-knife raised?
T-knife has raised a total of $187.2M across 2 funding rounds:
Series A
$77.2M
Series B
$110M
Series A (2020): $77.2M with participation from RA Capital Management, Versant Ventures, Andera Partners, and Boehringer Ingelheim Venture Fund
Series B (2021): $110M led by Fidelity Investments, Versant Ventures, Caas Capital Management, Sixty Degree Capital, RA Capital Management, Qatar Investment Authority, Life Sciences Partners, and Casdin Capital
Key Investors in T-knife
Fidelity Investments
Fidelity Investments is a financial services firm offering a wide array of investment, wealth management, and retirement planning solutions. They provide access to investment products, financial planning resources, and trading platforms to individual investors, businesses, and institutions.
Versant Ventures
Versant Ventures is a venture capital firm that partners with entrepreneurs to establish and fund innovative biotechnology companies globally. With substantial assets under management, they have a strong history of successful IPOs and M&A transactions in the biotech sector.
Caas Capital Management
CaaS Capital Management is a global investment manager and family office that focuses on cultivating relationships and strategically allocating capital. They engage in venture capital by investing in private companies, emphasizing long-term partnerships with founders.
What's next for T-knife?
The substantial enterprise-level funding T-knife has attracted indicates a strong belief in its therapeutic pipeline and market potential. This capital infusion is expected to fuel further research and development, clinical trials, and potential commercialization efforts. The company's trajectory suggests a focus on scaling its operations and advancing its lead candidates through the development pathway, positioning it for future growth and strategic partnerships within the biopharmaceutical sector.
See full T-knife company page
